Review Article
Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
Table 4
Result of sensitivity analysis.
| Variable | Patients (rifaximin/control) | Pooled RR | |
| All in Europe [24ā29] | 231 (113/118) | 3.16 [0.92, 10.93] | 0.07 | Acute HE [21, 27, 30] | 157 (82/75) | 0.77 [0.20, 2.93] | 0.70 | Chronic HE [26, 28, 29] | 107 (54/53) | 7.6 [1.87, 30.78] | 0.005 |
|
|
HE: hepatic encephalopathy; control lactulose or lactitol; RR: relative risk.
|